Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (CORAL)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Atherosclerosis Cardiovascular Diseases Hypertension, Renovascular Renal Artery Obstruction | Drug: Atacand/HCT, Caduet Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting) | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) |
- Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy [ Time Frame: Measured at every 3 months for the first year and annually thereafter ]Only the first event per participant is included in the composite
- Cardiovascular or Renal Death [ Time Frame: Measured at every 3 months for the first year and annually thereafter ]
- Myocardial Infarction [ Time Frame: Measured at every 3 months for the first year and annually thereafter ]
- Hospitalization for Congestive Heart Failure [ Time Frame: Measured at every 3 months for the first year and annually thereafter ]
- Stroke [ Time Frame: Measured at every 3 months for the first year and annually thereafter ]
- 30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days [ Time Frame: Measured at every 3 months for the first year and annually thereafter ]
- Need for Renal Replacement Therapy [ Time Frame: Measured at every 3 months for the first year and annually thereafter ]
| Enrollment: | 947 |
| Study Start Date: | April 2004 |
| Study Completion Date: | September 2013 |
| Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Optimal Medical Therapy
Optimal anti-hypertensive therapy
|
Drug: Atacand/HCT, Caduet
Atacand/HCT and caduet or optimal medical therapy for hypertension
|
|
Experimental: Stenting
Stent procedure plus optimal anti-hypertensive therapy
|
Procedure: GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)
Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
-
Either
- Documented history of hypertension on two or more anti-hypertensive medications OR
- Renal dysfunction, defined as Stage 3 or greater chronic kidney disease (CKD) based on the new National Kidney Foundation (NKF) classifications (estimated glomerular filtration rate [GFR] less than 60 mL per minute per 1.73 m^2, calculated by the modified Modification of Diet in Renal Disease [MDRD] formula)
-
One or more severe renal artery stenoses by any of the following pathways:
a. Angiographic: greater than or equal to 60% and less than 100% by renal angiogram OR b. Duplex: systolic velocity of greater than 300 cm/sec OR c. Core Lab approved Magnetic Resonance Angiogram (MRA) (refer to the protocol for specific criteria) demonstrating stenosis greater than 80% OR stenosis greater than 70% with spin dephasing on 3D phase contrast MRA OR stenosis greater than 70% and two of the following: i. Ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Ischemic kidney enhances less on arterial phase iii. Ischemic kidney has delayed Gd excretion iv. Ischemic kidney hyper-concentrates the urine v. 2-D phase contrast flow waveform shows delayed systolic peak vi. Post-stenotic dilatation d. Clinical index of suspicion combined with a Core Lab approved Computed Tomography Angiography (CTA) demonstrating Stenosis is greater than 80% by visual assessment on high quality CTA Stenosis is greater than 70% on CTA by visual assessment and there are two of the following i. The length of the ischemic kidney is greater than 1 cm. smaller than contralateral kidney ii. Reduced cortical thickness of ischemic kidney iii. Less cortical enhancement of ischemic kidney on arterial phase iv. Post-stenotic dilatation
EXCLUSION CRITERIA:
- Unable to provide informed consent
- Unable or willing to comply with study protocol or procedures
- Must be greater than 18 years of age
- Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be present prior to randomization
- Pregnancy or unknown pregnancy status in female of childbearing potential
- Participation in any drug or device trial during the study period, unless approved by the Steering Committee
- Prior enrollment in the CORAL study
- History of stroke within 6 months, if associated with a residual neurologic deficit*
- Any major surgery, major trauma, revascularization procedure, unstable angina, or myocardial infarction 30 days prior to study entry*
- Any planned major surgery or revascularization procedure, outside of the randomly allocated renal stenting indicated by the protocol, after randomization*
- Hospitalization for heart failure within 30 days*
- Comorbid condition causing life expectancy of less than or equal to 3 years*
- Allergic reaction to intravascular contrast, not amenable to pre-treatment
- Allergy to stainless steel
- Allergy to all of the following: aspirin, clopidogrel, ticlopidine
- Known untreated aneurysm of the abdominal aorta greater than 5.0 cm.*
- Previous kidney transplant
- a. Stenosis of greater than 50% of a previously treated revascularized renal artery OR b. Treatment of any renal artery stenosis within the past 9 months (roll-in patients can have prior treatment on the contralateral side)
- Kidney size less than 7 cm. supplied by target vessel
- Hydronephrosis, nephritis or other known cause of renal insufficiency, not due to large vessel renal artery stenosis
- Visualized stenosis of only an accessory renal artery supplying greater than 1/2 of the ipsilateral renal parenchyma, without stenosis in a dominant renal artery
- Local lab serum Cr greater than 4.0 mg/dl on the day of randomization*
-
Presence of a renal artery stenosis not amenable for treatment with a stent, known to be present prior to randomization
- The index lesion cannot be treated with a single stent (i.e. greater than 18 mm. in length)
- The placement of a stent will necessitate covering a renal artery branch renal artery with a stent
- The stenosis is in an artery less than 3.5 mm. in diameter
- The stenosis involves a segmental renal artery branch
- Abrupt vessel closure or dissection after diagnostic angiography [NOTE: Patients with abrupt vessel closure or dissection as a result of diagnostic angiography will not be randomized but will undergo stent revascularization, receive optimal medical therapy and will be followed for the full study period] *Roll-in patients do not need to meet these inclusion/exclusion criteria
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00081731
| United States, Ohio | |
| University of Toledo | |
| Toledo, Ohio, United States, 43614 | |
| Principal Investigator: | David Cohen, MD | Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO |
| Principal Investigator: | Christopher J. Cooper, MD | University of Toledo |
| Principal Investigator: | Donald Cutlip, MD | Beth Israel Deaconess Medcial Center |
| Principal Investigator: | Alan Matsumoto, MD | University of Virginia School of Medicine |
| Principal Investigator: | Michael Steffes, MD | University of Minnesota - Clinical and Translational Science Institute |
| Principal Investigator: | Timothy P Murphy, MD | Rhode Island Hospital |
| Study Chair: | Scott D Solomon, MD | Brigham and Women's Hospital |
| Study Chair: | Lance D Dworkin, MD | Rhode Island Hospital |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Baim Institute for Clinical Research |
| ClinicalTrials.gov Identifier: | NCT00081731 History of Changes |
| Other Study ID Numbers: |
161 U01HL071556 ( U.S. NIH Grant/Contract ) |
| Study First Received: | April 19, 2004 |
| Results First Received: | December 9, 2013 |
| Last Updated: | September 18, 2015 |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Atherosclerosis Renal Artery Obstruction Hypertension, Renovascular Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Kidney Diseases Urologic Diseases Hypertension, Renal Hypertension Candesartan cilexetil Candesartan |
Amlodipine, atorvastatin drug combination Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Lipid Regulating Agents Calcium Channel Blockers Membrane Transport Modulators Hydroxymethylglutaryl-CoA Reductase Inhibitors Enzyme Inhibitors |
ClinicalTrials.gov processed this record on July 17, 2017


IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
